Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

WILLIAM SEGER

Allopathic & Osteopathic Physicians Family Medicine

NPI
1417927971
CMS profile
199728
Location
FORT WORTH, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$1,710.22

126 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,697.87 125
Education $12.35 1

By paying entity

PY2019 · entire year · sorted by reported total

Page 3 of 3; records 101–126 of 126 matching records. This page contains 26 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

WILLIAM SEGER

NPI 1417927971 · CMS profile ID 199728

Allopathic & Osteopathic Physicians / Family Medicine

FORT WORTH, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–126 of 126 matching records. This page contains 26 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1417927971?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
WILLIAM SEGER, NPI 1417927971, CMS profile ID 199728. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–126 of 126 matching records. This page contains 26 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417927971?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). WILLIAM SEGER, NPI 1417927971, CMS profile ID 199728. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–126 of 126 matching records. This page contains 26 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417927971?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
WILLIAM SEGER, NPI 1417927971, CMS profile ID 199728, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–126 of 126 matching records. This page contains 26 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1417927971?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

126 matching records · $1,710.22 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 126 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–126 of 126.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $3.6902/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670209823 CMS
Abbott Laboratories $19.6602/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 664391523 CMS
Merck Sharp & Dohme Corporation $8.0902/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695295583 CMS
Astellas Pharma US Inc $14.7102/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655755715 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $11.4302/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684931321 CMS
PFIZER INC. $11.5102/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672179840 CMS
Novartis Pharmaceuticals Corporation $17.1002/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660200541 CMS
PFIZER INC. $4.9902/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672232207 CMS
Sunovion Pharmaceuticals Inc. $1.0802/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688096551 CMS
AstraZeneca Pharmaceuticals LP $121.5902/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685583707 CMS
Novo Nordisk Inc $12.2902/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 668791571 CMS
E.R. Squibb & Sons, L.L.C. $11.2101/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651366029 CMS
GlaxoSmithKline, LLC. $8.4101/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670205603 CMS
GlaxoSmithKline, LLC. $1.2401/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671107191 CMS
PFIZER INC. $23.3601/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672133109 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $7.1301/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700356105 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.2201/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684931319 CMS
Genentech USA, Inc. $13.9801/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681352391 CMS
Merck Sharp & Dohme Corporation $11.9901/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695247723 CMS
Sunovion Pharmaceuticals Inc. $15.4901/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688096549 CMS
Sunovion Pharmaceuticals Inc. $3.1201/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688096547 CMS
Amgen Inc. $10.8801/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663185859 CMS
AstraZeneca Pharmaceuticals LP $136.6301/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685654763 CMS
GlaxoSmithKline, LLC. $8.6201/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671026817 CMS
AstraZeneca Pharmaceuticals LP $12.0401/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685081404 CMS
PFIZER INC. $10.6701/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672162843 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,710.22 126
PY2020 $824.55 56
PY2021 $870.68 57
PY2022 $1,303.01 89
PY2023 $1,177.94 81
PY2024 $966.07 65
PY2025 $930.16 58

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,891,022.48 334
PY2024 Recipient $3,200.00 1
PY2024 Principal investigator $3,725,318.03 333
PY2023 Principal investigator $5,662,721.18 2,144
PY2022 Principal investigator $6,424,241.89 584
PY2021 Principal investigator $6,369,174.56 321
PY2020 Principal investigator $1,991,482.37 385
PY2019 Principal investigator $1,391,006.52 909

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

334 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $54.64 12/23/2025 Non-covered Recipient Entity
BENCHMARK RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996808
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266119
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266121
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266123
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266125
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266127
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266185
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266187
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266189
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266191
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266193
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266195
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266197
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266199
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266201
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266203
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266206
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266209
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266211
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266213
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266215
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266217
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266219
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266221
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266223
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266225
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266227
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266231
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266233
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266235
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266237
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266239
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266241
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266243
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266245
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266247
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266249
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266251
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266253
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266255
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266257
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266259
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266261
Principal investigator 1 Seqirus USA Inc $793.50 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266263
Principal investigator 1 Seqirus USA Inc $793.50 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266265
Principal investigator 1 Seqirus USA Inc $385.02 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266275
Principal investigator 1 Seqirus USA Inc $385.02 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266277
Principal investigator 1 Seqirus USA Inc $385.02 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266279
Principal investigator 1 Seqirus USA Inc $385.02 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266281
Principal investigator 1 Seqirus USA Inc $385.02 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266283
Principal investigator 1 Seqirus USA Inc $385.02 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266393
Principal investigator 1 Seqirus USA Inc $793.50 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266395
Principal investigator 1 Seqirus USA Inc $1,080.54 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266399
Principal investigator 1 Seqirus USA Inc $1,207.50 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266401
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266405
Principal investigator 1 Seqirus USA Inc $1,207.50 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266415
Principal investigator 1 Seqirus USA Inc $1,080.54 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266417
Principal investigator 1 Seqirus USA Inc $1,080.54 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266419
Principal investigator 1 Seqirus USA Inc $1,080.54 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266421
Principal investigator 1 Seqirus USA Inc $1,080.54 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266423
Principal investigator 1 Seqirus USA Inc $1,080.54 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266425
Principal investigator 1 Seqirus USA Inc $1,080.54 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266427
Principal investigator 1 Seqirus USA Inc $1,080.54 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266429
Principal investigator 1 Seqirus USA Inc $1,080.54 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266431
Principal investigator 1 Seqirus USA Inc $1,080.54 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266433
Principal investigator 1 Seqirus USA Inc $1,080.54 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266435
Principal investigator 1 Seqirus USA Inc $1,080.54 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266437
Principal investigator 1 Seqirus USA Inc $1,080.54 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266439
Principal investigator 1 Seqirus USA Inc $1,080.54 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266441
Principal investigator 1 Seqirus USA Inc $1,080.54 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266443
Principal investigator 1 Seqirus USA Inc $1,080.54 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266445
Principal investigator 1 Seqirus USA Inc $1,080.54 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266447
Principal investigator 1 Seqirus USA Inc $1,080.54 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266449
Principal investigator 1 Seqirus USA Inc $1,080.54 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266451
Principal investigator 1 Seqirus USA Inc $1,080.54 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266453
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266455
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266457
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266459
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266461
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266463
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266465
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266467
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266469
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266471
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266473
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266475
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266477
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266479
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266481
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266483
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266486
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266489
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266491
Principal investigator 1 Seqirus USA Inc $3,268.53 12/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266493
Principal investigator 1 ModernaTX, Inc. $1,800.00 12/17/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252996726
Principal investigator 1 ModernaTX, Inc. $800.00 12/17/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252996728
Principal investigator 1 ModernaTX, Inc. $600.00 12/17/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252996770
Principal investigator 1 ModernaTX, Inc. $75.00 12/17/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252996800
Principal investigator 1 ModernaTX, Inc. $2,000.00 12/17/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252996804
Principal investigator 1 ModernaTX, Inc. $1,200.00 12/17/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252996853
Principal investigator 1 ModernaTX, Inc. $1,657.50 12/15/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996861
Principal investigator 1 ModernaTX, Inc. $244.00 12/15/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996887
Principal investigator 1 ModernaTX, Inc. $24,252.75 12/05/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252968183
Principal investigator 1 ModernaTX, Inc. $318.50 12/04/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996736
Principal investigator 1 ModernaTX, Inc. $1,860.00 11/27/2025 Non-covered Recipient Entity
Benchmark Research
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age No dispute reported 06/30/2026 1252968125
Principal investigator 1 ModernaTX, Inc. $2,966.00 11/27/2025 Non-covered Recipient Entity
Benchmark Research
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age No dispute reported 06/30/2026 1252968193
Principal investigator 1 ModernaTX, Inc. $600.00 11/27/2025 Non-covered Recipient Entity
Benchmark Research
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age No dispute reported 06/30/2026 1252968213
Principal investigator 1 ModernaTX, Inc. $2,000.00 11/27/2025 Non-covered Recipient Entity
Benchmark Research
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age No dispute reported 06/30/2026 1252968215
Principal investigator 1 ModernaTX, Inc. $4,284.00 11/27/2025 Non-covered Recipient Entity
Benchmark Research
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age No dispute reported 06/30/2026 1252968217
Principal investigator 1 ModernaTX, Inc. $1,800.00 11/27/2025 Non-covered Recipient Entity
Benchmark Research
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age No dispute reported 06/30/2026 1252968219
Principal investigator 1 ModernaTX, Inc. $10,600.00 11/27/2025 Non-covered Recipient Entity
Benchmark Research
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age No dispute reported 06/30/2026 1252968223
Principal investigator 1 ModernaTX, Inc. $50,933.28 11/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996810
Principal investigator 1 ModernaTX, Inc. $671.84 11/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996814
Principal investigator 1 ModernaTX, Inc. $7,349.76 11/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996825
Principal investigator 1 ModernaTX, Inc. $136.60 11/26/2025 Non-covered Recipient Entity
Benchmark Research
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996822
Principal investigator 1 PFIZER INC. $9,660.00 11/26/2025 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228712840
Principal investigator 1 ModernaTX, Inc. $250.00 11/14/2025 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252968107
Principal investigator 1 ModernaTX, Inc. $4,490.10 11/14/2025 Non-covered Recipient Entity
QCARE SITE SERVICES
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252968199
Principal investigator 1 PFIZER INC. $1,277.78 10/31/2025 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228824286
Principal investigator 1 Seqirus USA Inc $3,846.60 10/31/2025 Non-covered Recipient Entity
Avacare Clinical Research Network
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250809500
Principal investigator 1 Seqirus USA Inc $1,057.05 10/31/2025 Non-covered Recipient Entity
Avacare Clinical Research Network
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250809504
Principal investigator 1 ModernaTX, Inc. $78.00 10/29/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996752
Principal investigator 1 ModernaTX, Inc. $199.56 10/29/2025 Non-covered Recipient Entity
BENCHMARK RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996774
Principal investigator 1 ModernaTX, Inc. $6,100.00 10/29/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996843
Principal investigator 1 ModernaTX, Inc. $5,038.80 10/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996742
Principal investigator 1 ModernaTX, Inc. $7,158.36 10/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996758
Principal investigator 1 ModernaTX, Inc. $811.40 10/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996764
Principal investigator 1 PFIZER INC. $388.00 10/25/2025 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228824771
Principal investigator 1 PFIZER INC. $1,500.00 10/25/2025 Non-covered Recipient Entity
LSB Research Group LLC dba Benchmark Research
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228824833
Principal investigator 1 ModernaTX, Inc. $2,250.00 10/22/2025 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252968147
Principal investigator 1 Seqirus USA Inc $2,000.00 10/17/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266403
Principal investigator 1 Seqirus USA Inc $3,500.00 10/17/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266407
Principal investigator 1 Seqirus USA Inc $15,000.00 10/17/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266409
Principal investigator 1 ModernaTX, Inc. $2,400.00 10/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252968127
Principal investigator 1 ModernaTX, Inc. $1,050.00 10/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252968129
Principal investigator 1 ModernaTX, Inc. $700.00 10/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252968197
Principal investigator 1 ModernaTX, Inc. $78.00 10/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996780
Principal investigator 1 ModernaTX, Inc. $1,060.80 10/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996792
Principal investigator 1 ModernaTX, Inc. $1,622.40 10/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996859
Principal investigator 1 ModernaTX, Inc. $1,952.00 10/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996883
Principal investigator 1 PFIZER INC. $21,272.65 10/08/2025 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228824778
Principal investigator 1 ModernaTX, Inc. $6,382.48 09/29/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996831
Principal investigator 1 ModernaTX, Inc. $6,737.28 09/29/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996841
Principal investigator 1 PFIZER INC. $3,000.00 09/24/2025 Non-covered Recipient Entity
LSB Research Group LLC dba Benchmark Research
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228837332
Principal investigator 1 ModernaTX, Inc. $318.50 09/22/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996827
Principal investigator 1 Seqirus USA Inc $110.98 09/18/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266389
Principal investigator 1 Seqirus USA Inc $111.30 09/18/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266391
Principal investigator 1 Seqirus USA Inc $946.80 09/18/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185266397
Principal investigator 1 ModernaTX, Inc. $400.00 09/17/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252968151
Principal investigator 1 ModernaTX, Inc. $700.00 09/17/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252968153
Principal investigator 1 ModernaTX, Inc. $900.00 09/17/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252968187
Principal investigator 1 ModernaTX, Inc. $1,892.70 09/12/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252968131
Principal investigator 1 ModernaTX, Inc. $11,300.00 09/11/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252996724
Principal investigator 1 ModernaTX, Inc. $2,250.00 09/11/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252996730
Principal investigator 1 ModernaTX, Inc. $8,400.00 09/11/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252996732
Principal investigator 1 ModernaTX, Inc. $3,000.00 09/11/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252996802
Principal investigator 1 ModernaTX, Inc. $1,050.00 09/11/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252996849
Principal investigator 1 ModernaTX, Inc. $2,775.00 09/11/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252996851
Principal investigator 1 ModernaTX, Inc. $20,668.50 09/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252968115
Principal investigator 1 ModernaTX, Inc. $2,500.00 09/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252968117
Principal investigator 1 ModernaTX, Inc. $742.50 09/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252968149
Principal investigator 1 Seqirus USA Inc $420.00 09/10/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266353
Principal investigator 1 Seqirus USA Inc $24.00 09/10/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266355
Principal investigator 1 Seqirus USA Inc $164.28 09/10/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266357
Principal investigator 1 ModernaTX, Inc. $318.50 09/03/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996766
Principal investigator 1 ModernaTX, Inc. $18,475.60 08/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996762
Principal investigator 1 ModernaTX, Inc. $7,866.54 08/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996879
Principal investigator 1 ModernaTX, Inc. $4,456.88 08/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996891
Principal investigator 1 ModernaTX, Inc. $418.66 08/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002485
Principal investigator 1 ModernaTX, Inc. $138.32 08/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011232
Principal investigator 1 ModernaTX, Inc. $3,888.40 08/20/2025 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252968203
Principal investigator 1 ModernaTX, Inc. $4,860.50 08/01/2025 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252968181
Principal investigator 1 ModernaTX, Inc. $76,950.00 08/01/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252968185
Principal investigator 1 ModernaTX, Inc. $1,837.44 07/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996744
Principal investigator 1 ModernaTX, Inc. $7,799.54 07/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996778
Principal investigator 1 ModernaTX, Inc. $9,652.50 07/23/2025 Non-covered Recipient Entity
QCARE SITE SERVICES
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252968135
Principal investigator 1 ModernaTX, Inc. $5,031.45 07/23/2025 Non-covered Recipient Entity
QCARE SITE SERVICES
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252968171
Principal investigator 1 Seqirus USA Inc $900.00 07/18/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266369
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,900.00 07/16/2025 Non-covered Recipient Entity
BENCHMARK RESEARCH
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185546143
Principal investigator 1 Seqirus USA Inc $172.00 07/14/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266361
Principal investigator 1 Seqirus USA Inc $1,200.00 07/14/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266363
Principal investigator 1 Seqirus USA Inc $8,500.00 07/14/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266365
Principal investigator 1 Seqirus USA Inc $1,500.00 07/14/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266367
Principal investigator 1 Seqirus USA Inc $1,500.00 07/14/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266377
Principal investigator 1 PFIZER INC. $3,712.00 07/11/2025 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228846932
Principal investigator 1 PFIZER INC. $184.65 07/07/2025 Non-covered Recipient Entity
Benchmark Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228712842
Principal investigator 1 PFIZER INC. $216.45 07/07/2025 Non-covered Recipient Entity
Benchmark Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228712844
Principal investigator 1 ModernaTX, Inc. $114.75 07/02/2025 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252968105
Principal investigator 1 ModernaTX, Inc. $4,374.45 07/02/2025 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252968201
Principal investigator 1 Seqirus USA Inc $2,350.00 07/02/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266345
Principal investigator 1 Seqirus USA Inc $1,500.00 07/02/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266347
Principal investigator 1 Seqirus USA Inc $1,200.00 07/02/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266349
Principal investigator 1 Seqirus USA Inc $1,800.00 07/02/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266351
Principal investigator 1 PFIZER INC. $4,300.00 07/01/2025 Non-covered Recipient Entity
Qcare Site Services Inc dba Avacare
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228846939
Principal investigator 1 ModernaTX, Inc. $5,742.00 06/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996829
Principal investigator 1 ModernaTX, Inc. $2,687.36 06/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996877
Principal investigator 1 ModernaTX, Inc. $7,799.54 06/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996881
Principal investigator 1 ModernaTX, Inc. $2,450.25 06/25/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252968133
Principal investigator 1 ModernaTX, Inc. $900.00 06/25/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252968137
Principal investigator 1 ModernaTX, Inc. $364.50 06/25/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252968161
Principal investigator 1 ModernaTX, Inc. $121.50 06/25/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252968163
Principal investigator 1 ModernaTX, Inc. $1,200.00 06/25/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252968165
Principal investigator 1 ModernaTX, Inc. $22,889.25 06/18/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252968169
Principal investigator 1 ModernaTX, Inc. $2,434.20 06/18/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996738
Principal investigator 1 ModernaTX, Inc. $5,374.72 06/18/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996790
Principal investigator 1 ModernaTX, Inc. $6,469.32 06/18/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996796
Principal investigator 1 ModernaTX, Inc. $25,627.06 06/18/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996816
Principal investigator 1 ModernaTX, Inc. $2,093.30 06/18/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002483
Principal investigator 1 ModernaTX, Inc. $528.00 06/04/2025 Non-covered Recipient Entity
BENCHMARK RESEARCH
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age No dispute reported 06/30/2026 1252968211
Principal investigator 1 ModernaTX, Inc. $245.00 06/04/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011222
Principal investigator 1 ModernaTX, Inc. $23,962.50 05/28/2025 Non-covered Recipient Entity
BENCHMARK RESEARCH
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age No dispute reported 06/30/2026 1252968121
Principal investigator 1 ModernaTX, Inc. $6,521.85 05/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252968167
Principal investigator 1 ModernaTX, Inc. $57,939.44 05/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996734
Principal investigator 1 ModernaTX, Inc. $13,772.72 05/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996748
Principal investigator 1 ModernaTX, Inc. $7,215.78 05/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996871
Principal investigator 1 ModernaTX, Inc. $55,681.78 05/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011214
Principal investigator 1 ModernaTX, Inc. $1,420.25 05/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011228
Principal investigator 1 ModernaTX, Inc. $11,520.08 05/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011236
Principal investigator 1 ModernaTX, Inc. $83,868.75 05/22/2025 Non-covered Recipient Entity
BENCHMARK RESEARCH
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age No dispute reported 06/30/2026 1252968221
Principal investigator 1 ModernaTX, Inc. $486.05 05/21/2025 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252968109
Principal investigator 1 ModernaTX, Inc. $39.00 05/15/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996835
Principal investigator 1 ModernaTX, Inc. $2,121.60 05/15/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996837
Principal investigator 1 ModernaTX, Inc. $70,842.60 05/14/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252968113
Principal investigator 1 ModernaTX, Inc. $1,500.00 05/14/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996865
Principal investigator 1 ModernaTX, Inc. $22,634.10 05/07/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252968195
Principal investigator 1 PFIZER INC. $898.43 05/07/2025 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228857518
Principal investigator 1 ModernaTX, Inc. $33,256.08 04/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996812
Principal investigator 1 ModernaTX, Inc. $6,679.86 04/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996847
Principal investigator 1 ModernaTX, Inc. $1,622.80 04/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996873
Principal investigator 1 ModernaTX, Inc. $19,258.36 04/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002489
Principal investigator 1 ModernaTX, Inc. $19,028.88 04/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011224
Principal investigator 1 ModernaTX, Inc. $12,782.25 04/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011226
Principal investigator 1 ModernaTX, Inc. $3,773.40 04/23/2025 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252968143
Principal investigator 1 Seqirus USA Inc $638.00 04/09/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266295
Principal investigator 1 Seqirus USA Inc $638.00 04/09/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266297
Principal investigator 1 Seqirus USA Inc $638.00 04/09/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266299
Principal investigator 1 Seqirus USA Inc $638.00 04/09/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266301
Principal investigator 1 Seqirus USA Inc $638.00 04/09/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266303
Principal investigator 1 Seqirus USA Inc $638.00 04/09/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266305
Principal investigator 1 Seqirus USA Inc $1,291.00 04/09/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266307
Principal investigator 1 Seqirus USA Inc $638.00 04/09/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266309
Principal investigator 1 Seqirus USA Inc $638.00 04/09/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266311
Principal investigator 1 Seqirus USA Inc $638.00 04/09/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266313
Principal investigator 1 Seqirus USA Inc $638.00 04/09/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266315
Principal investigator 1 Seqirus USA Inc $638.00 04/09/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266317
Principal investigator 1 Seqirus USA Inc $638.00 04/09/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266319
Principal investigator 1 Seqirus USA Inc $638.00 04/09/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266321
Principal investigator 1 Seqirus USA Inc $638.00 04/09/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266323
Principal investigator 1 Seqirus USA Inc $1,291.00 04/09/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266325
Principal investigator 1 Seqirus USA Inc $638.00 04/09/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266327
Principal investigator 1 Seqirus USA Inc $638.00 04/09/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266329
Principal investigator 1 Seqirus USA Inc $638.00 04/09/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266331
Principal investigator 1 Seqirus USA Inc $638.00 04/09/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266333
Principal investigator 1 Seqirus USA Inc $638.00 04/09/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266335
Principal investigator 1 Seqirus USA Inc $638.00 04/09/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266337
Principal investigator 1 Seqirus USA Inc $1,291.00 04/09/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266555
Principal investigator 1 Seqirus USA Inc $638.00 04/09/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266557
Principal investigator 1 Seqirus USA Inc $638.00 04/09/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266559
Principal investigator 1 Seqirus USA Inc $1,291.00 04/09/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266561
Principal investigator 1 Seqirus USA Inc $638.00 04/09/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266563
Principal investigator 1 Seqirus USA Inc $638.00 04/09/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266565
Principal investigator 1 Seqirus USA Inc $638.00 04/09/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266567
Principal investigator 1 Seqirus USA Inc $638.00 04/09/2025 Non-covered Recipient Entity
Qcare Site Services Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185266569
Principal investigator 1 ModernaTX, Inc. $156.00 04/01/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996784
Principal investigator 1 ModernaTX, Inc. $12,870.00 04/01/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002487
Principal investigator 1 ModernaTX, Inc. $182.00 04/01/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011216
Principal investigator 1 ModernaTX, Inc. $1,170.00 03/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011218
Principal investigator 1 ModernaTX, Inc. $9,585.00 03/24/2025 Non-covered Recipient Entity
BENCHMARK RESEARCH
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age No dispute reported 06/30/2026 1252968123
Principal investigator 1 ModernaTX, Inc. $3,245.60 03/24/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996746
Principal investigator 1 ModernaTX, Inc. $6,105.66 03/24/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996754
Principal investigator 1 ModernaTX, Inc. $9,903.42 03/24/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996845
Principal investigator 1 ModernaTX, Inc. $30,568.72 03/24/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996863
Principal investigator 1 ModernaTX, Inc. $2,511.96 03/24/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002497
Principal investigator 1 ModernaTX, Inc. $17,210.96 03/24/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011208
Principal investigator 1 ModernaTX, Inc. $11,362.00 03/24/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011210
Principal investigator 1 PFIZER INC. $4,002.04 03/22/2025 Non-covered Recipient Entity
LSB Research Group LLC dba Benchmark Research
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228862098
Principal investigator 1 PFIZER INC. $2,228.16 03/22/2025 Non-covered Recipient Entity
Qcare Site Services Inc dba Avacare
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228862799
Principal investigator 1 ModernaTX, Inc. $675.00 03/19/2025 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252968141
Principal investigator 1 ModernaTX, Inc. $2,430.25 03/19/2025 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252968179
Principal investigator 1 PFIZER INC. $898.43 03/12/2025 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228862992
Principal investigator 1 PFIZER INC. $4,492.15 03/05/2025 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228863002
Principal investigator 1 ModernaTX, Inc. $3,981.12 02/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996760
Principal investigator 1 ModernaTX, Inc. $3,151.72 02/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996794
Principal investigator 1 ModernaTX, Inc. $9,876.42 02/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996820
Principal investigator 1 ModernaTX, Inc. $7,751.70 02/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996833
Principal investigator 1 ModernaTX, Inc. $27,881.36 02/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996839
Principal investigator 1 ModernaTX, Inc. $16,505.70 02/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996855
Principal investigator 1 ModernaTX, Inc. $33,285.20 02/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996869
Principal investigator 1 ModernaTX, Inc. $811.40 02/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996875
Principal investigator 1 ModernaTX, Inc. $8,032.48 02/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002491
Principal investigator 1 ModernaTX, Inc. $9,941.75 02/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011206
Principal investigator 1 ModernaTX, Inc. $516.24 02/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011212
Principal investigator 1 ModernaTX, Inc. $44,796.62 02/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011220
Principal investigator 1 ModernaTX, Inc. $33,018.96 02/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011230
Principal investigator 1 ModernaTX, Inc. $600.00 02/26/2025 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252968139
Principal investigator 1 ModernaTX, Inc. $2,605.50 02/26/2025 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252968175
Principal investigator 1 ModernaTX, Inc. $229.50 02/26/2025 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252968177
Principal investigator 1 PFIZER INC. $1,796.86 02/26/2025 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228838034
Principal investigator 1 PFIZER INC. $8,004.08 02/22/2025 Non-covered Recipient Entity
LSB Research Group LLC dba Benchmark Research
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228837338
Principal investigator 1 ModernaTX, Inc. $7,316.80 02/21/2025 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252968145
Principal investigator 1 ModernaTX, Inc. $1,060.80 02/19/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996776
Principal investigator 1 ModernaTX, Inc. $7,300.00 02/14/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996740
Principal investigator 1 ModernaTX, Inc. $1,500.00 02/14/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996750
Principal investigator 1 ModernaTX, Inc. $1,723.80 02/14/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996782
Principal investigator 1 ModernaTX, Inc. $1,100.00 02/14/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996867
Principal investigator 1 ModernaTX, Inc. $455.00 02/14/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996885
Principal investigator 1 ModernaTX, Inc. $2,000.00 02/14/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996889
Principal investigator 1 PFIZER INC. $1,143.44 02/05/2025 Non-covered Recipient Entity
LSB Research Group LLC dba Benchmark Research
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228837346
Principal investigator 1 PFIZER INC. $5,717.20 01/30/2025 Non-covered Recipient Entity
LSB Research Group LLC dba Benchmark Research
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228862583
Principal investigator 1 ModernaTX, Inc. $5,545.10 01/29/2025 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252968173
Principal investigator 1 ModernaTX, Inc. $125.00 01/29/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252996772
Principal investigator 1 ModernaTX, Inc. $29,840.40 01/29/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252996798
Principal investigator 1 ModernaTX, Inc. $3,655.74 01/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996756
Principal investigator 1 ModernaTX, Inc. $267.96 01/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996768
Principal investigator 1 ModernaTX, Inc. $22,062.04 01/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996786
Principal investigator 1 ModernaTX, Inc. $15,452.32 01/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996788
Principal investigator 1 ModernaTX, Inc. $811.40 01/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996806
Principal investigator 1 ModernaTX, Inc. $15,405.32 01/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996857
Principal investigator 1 ModernaTX, Inc. $23,020.40 01/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002493
Principal investigator 1 ModernaTX, Inc. $82,332.92 01/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002495
Principal investigator 1 ModernaTX, Inc. $6,698.56 01/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002499
Principal investigator 1 ModernaTX, Inc. $29,112.60 01/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011234
Principal investigator 1 PFIZER INC. $317.40 01/25/2025 Non-covered Recipient Entity
Qcare Site Services Inc dba Avacare
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228863621
Principal investigator 1 ModernaTX, Inc. $90.00 01/24/2025 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas No dispute reported 06/30/2026 1252968119
Principal investigator 1 ModernaTX, Inc. $6,307.00 01/24/2025 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas No dispute reported 06/30/2026 1252968155
Principal investigator 1 ModernaTX, Inc. $2,250.00 01/24/2025 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas No dispute reported 06/30/2026 1252968157
Principal investigator 1 ModernaTX, Inc. $170.00 01/24/2025 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas No dispute reported 06/30/2026 1252968159
Principal investigator 1 ModernaTX, Inc. $3,968.00 01/24/2025 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas No dispute reported 06/30/2026 1252968189
Principal investigator 1 ModernaTX, Inc. $114.00 01/24/2025 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas No dispute reported 06/30/2026 1252968191
Principal investigator 1 ModernaTX, Inc. $8,625.00 01/24/2025 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas No dispute reported 06/30/2026 1252968205
Principal investigator 1 ModernaTX, Inc. $625.00 01/24/2025 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas No dispute reported 06/30/2026 1252968207
Principal investigator 1 ModernaTX, Inc. $110.00 01/24/2025 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas No dispute reported 06/30/2026 1252968209
Principal investigator 1 ModernaTX, Inc. $199.56 01/13/2025 Non-covered Recipient Entity
BENCHMARK RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996818
Principal investigator 1 ModernaTX, Inc. $5,487.60 01/03/2025 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252968111